Brief: Botanix Pharmaceuticals Responds To US Pharmaceutical Pricing Announcement
12/05/2025 03:30
May 12 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX: RESPONDS TO US PHARMACEUTICAL PRICING ANNOUNCEMENT DOES NOT CONSIDER LIKELY THAT IT WILL BE SUBJECT TO PRICE REDUCTIONS BASED ON SALES OF SOFDRA OUTSIDE USA Source text: ID:nASX80w4r0 Further company coverage: BOT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million